William Blair Reiterates Buy Rating for Biogen (BIIB)

William Blair reissued their buy rating on shares of Biogen (NASDAQ:BIIB) in a research report report published on Thursday.

A number of other research analysts have also weighed in on the stock. BidaskClub lowered shares of Biogen from a buy rating to a hold rating in a report on Thursday. Credit Suisse Group raised shares of Biogen to a buy rating and set a $384.00 target price for the company in a report on Wednesday, February 7th. JPMorgan Chase & Co. reissued a buy rating on shares of Biogen in a report on Thursday, February 8th. Canaccord Genuity reissued a hold rating and issued a $350.00 target price on shares of Biogen in a report on Wednesday, February 7th. Finally, Mizuho reissued a buy rating and issued a $433.00 target price (up from $400.00) on shares of Biogen in a report on Sunday, February 4th. Ten equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. Biogen currently has a consensus rating of Buy and an average target price of $368.99.

Biogen (NASDAQ:BIIB) opened at $291.87 on Thursday. Biogen has a fifty-two week low of $244.28 and a fifty-two week high of $370.57. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. The firm has a market cap of $61,748.89, a price-to-earnings ratio of 24.49, a P/E/G ratio of 1.52 and a beta of 0.75.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing analysts’ consensus estimates of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The business had revenue of $3.31 billion during the quarter, compared to analysts’ expectations of $3.08 billion. During the same period last year, the business posted $5.04 earnings per share. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. research analysts predict that Biogen will post 24.88 EPS for the current year.

In other news, Director Robert W. Pangia sold 5,832 shares of Biogen stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the sale, the director now directly owns 23,539 shares in the company, valued at $7,759,631.35. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michel Vounatsos bought 780 shares of the firm’s stock in a transaction dated Friday, December 29th. The shares were acquired at an average price of $320.55 per share, with a total value of $250,029.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 31,560 shares of company stock valued at $10,020,858. Corporate insiders own 0.25% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BIIB. Captrust Financial Advisors bought a new stake in shares of Biogen during the fourth quarter worth $113,000. Prentiss Smith & Co. Inc. bought a new stake in shares of Biogen during the fourth quarter worth $123,000. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Biogen by 77.0% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 174 shares during the last quarter. Horan Capital Advisors LLC. bought a new stake in shares of Biogen in the third quarter valued at about $128,000. Finally, Massey Quick Simon & CO. LLC raised its holdings in shares of Biogen by 84.8% in the third quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 195 shares in the last quarter. Institutional investors and hedge funds own 87.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “William Blair Reiterates Buy Rating for Biogen (BIIB)” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.thelincolnianonline.com/2018/02/18/william-blair-reiterates-buy-rating-for-biogen-biib.html.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Analyst Recommendations for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply